GSK’s Blenrep Gains Approval from Japanese Regulators

GSK has received approval for its Blenrep treatment for relapsed or refractory multiple myeloma from the Ministry of Health, Labour and Welfare in Japan. This approval follows positive results from two pivotal phase III trials, Dreamm-7 and Dreamm-8, which demonstrated significant advancements in treatment outcomes for patients.

This will be welcome news to holders of GSK shares (LON: GSK), having seen a 21.24% decline in the price over the past 12 months.

In the Dreamm-7 trial, Blenrep was combined with bortezomib and dexamethasone (BVd). This combination showed improved overall survival rates and significant progression-free survival compared to standard care. The Dreamm-8 trial evaluated Blenrep with pomalidomide and dexamethasone (BPd), where similar benefits were observed in progression-free survival.

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG

5.0

View Offers

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

Both trials underscored the potential of these Blenrep combinations to redefine treatment outcomes. Hesham Abdullah, GSK’s Senior Vice President and Global Head of Oncology at R&D, emphasized the impact these results could have on patient care.

An additional benefit of the Blenrep treatment is its in-office administration, making it convenient for healthcare providers and patients.

This development marks a significant milestone for GSK, highlighting its ongoing commitment to advancing cancer therapies and improving patient outcomes in oncology.